Post written by Thiruvengadam Muniraj, MD, from the Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA. Post-ERCP pancreatitis (PEP) is the most common adverse event after ERCP. Despite adoption of several strategies such as rectal indomethacin, pancreatic duct stent placement, and aggressive fluid administration, incidence of PEP remains substantial. Identifying patients who are likely to develop …
Continue reading Clinical predictive value of renalase in post-ERCP pancreatitis